Cipla Ltd. Technical Momentum Shifts Amid Bearish Signals

Current Price and Market Context

As of 5 Feb 2026, Cipla’s stock closed at ₹1,325.55, slightly up from the previous close of ₹1,322.45. The stock’s 52-week range remains wide, with a high of ₹1,672.20 and a low of ₹1,283.00, indicating significant volatility over the past year. Cipla’s market capitalisation grade stands at 1, reflecting its large-cap status but also signalling limited upside potential relative to peers.

Technical Trend Overview

The technical trend for Cipla has deteriorated from mildly bearish to outright bearish, a shift that warrants close attention. The daily moving averages are firmly bearish, indicating that the stock price is trading below key averages such as the 50-day and 200-day moving averages, which often serve as critical support and resistance levels. This bearish alignment suggests that the stock is under selling pressure in the short to medium term.

MACD and Momentum Indicators

The Moving Average Convergence Divergence (MACD) indicator presents a mixed but predominantly negative picture. On a weekly basis, the MACD remains bearish, signalling that the short-term momentum is weaker than the longer-term trend. The monthly MACD is mildly bearish, indicating that while the longer-term momentum is not strongly negative, it is far from bullish. This divergence between weekly and monthly MACD readings suggests that Cipla may face continued selling pressure in the near term, with limited signs of a sustained recovery.

RSI Signals Point to Divergent Momentum

Contrasting the MACD, the Relative Strength Index (RSI) readings are bullish on both weekly and monthly timeframes. This indicates that despite the bearish momentum suggested by other indicators, Cipla’s stock is not currently oversold and may have some underlying strength. The RSI’s bullish stance could imply that the stock is poised for short-term rebounds or consolidation phases, although this is tempered by the broader bearish context.

Bollinger Bands and Volatility Assessment

Bollinger Bands on both weekly and monthly charts are mildly bearish, reflecting moderate volatility with a downward bias. The stock price is likely trading near the lower band, which often acts as a support level but also signals increased downside risk if breached decisively. This mild bearishness in volatility measures aligns with the overall cautious technical outlook.

Additional Technical Indicators: KST, Dow Theory, and OBV

The Know Sure Thing (KST) oscillator is bearish on a weekly basis and mildly bearish monthly, reinforcing the negative momentum narrative. Dow Theory assessments show a mildly bearish trend weekly and no clear trend monthly, suggesting uncertainty in the broader market context for Cipla. Meanwhile, On-Balance Volume (OBV) is mildly bearish weekly and neutral monthly, indicating that volume trends are not strongly supporting a bullish reversal at this stage.

Comparative Performance Against Sensex

When analysing Cipla’s returns relative to the benchmark Sensex, the stock has underperformed significantly over recent periods. Over the past week, Cipla declined by 0.20% while Sensex gained 1.79%. The one-month and year-to-date returns for Cipla are deeply negative at -12.31% and -12.27% respectively, compared to Sensex’s modest declines of -2.27% and -1.65%. Over the one-year horizon, Cipla’s return of -8.50% contrasts sharply with Sensex’s positive 6.66% gain.

Longer-term returns show Cipla lagging the benchmark as well, with three-year returns at 29.57% versus Sensex’s 37.76%, five-year returns at 58.85% against 65.60%, and a ten-year return of 140.90% compared to Sensex’s robust 244.38%. This persistent underperformance highlights structural challenges and competitive pressures within Cipla’s business and sector.

Mojo Score and Rating Revision

MarketsMOJO’s proprietary scoring system currently assigns Cipla a Mojo Score of 36.0, categorising it with a Sell grade. This represents a downgrade from the previous Hold rating as of 7 Jan 2026. The downgrade reflects the deteriorating technical indicators and the company’s relative underperformance. The low Mojo Score and Sell grade suggest that investors should exercise caution and consider risk management strategies when holding or acquiring Cipla shares.

Implications for Investors

The confluence of bearish technical signals, including moving averages, MACD, KST, and Dow Theory, alongside Cipla’s underwhelming relative returns, paints a cautious picture for investors. While the bullish RSI readings offer some hope for short-term rebounds, the overall momentum remains negative. Investors should closely monitor key support levels near the 52-week low of ₹1,283.00 and watch for any sustained breakouts above resistance levels near ₹1,335.00, today’s high.

Given the current technical landscape, Cipla appears vulnerable to further downside pressure, especially if broader market conditions deteriorate or sector-specific headwinds intensify. Portfolio managers and traders may consider reducing exposure or employing hedging strategies until clearer signs of technical recovery emerge.

Sector and Industry Context

Cipla operates within the Pharmaceuticals & Biotechnology sector, a space characterised by rapid innovation, regulatory challenges, and intense competition. The sector’s performance often hinges on product pipelines, patent expiries, and global health trends. Cipla’s current technical weakness may reflect broader sector volatility as well as company-specific factors such as pricing pressures and margin constraints.

Investors should weigh Cipla’s technical signals against fundamental developments and sector outlooks. While the stock’s long-term returns remain positive, the recent technical deterioration suggests that near-term risks are elevated.

Summary and Outlook

In summary, Cipla Ltd.’s technical parameters have shifted towards a bearish stance, with multiple indicators confirming weakening momentum. The downgrade to a Sell grade by MarketsMOJO underscores the need for caution. Although some indicators like RSI suggest potential short-term strength, the prevailing trend is negative, and the stock’s relative underperformance versus Sensex adds to the risk profile.

Investors should monitor technical levels closely and consider alternative investment opportunities within the Pharmaceuticals & Biotechnology sector that may offer more favourable risk-reward profiles.

Unlock special upgrade rates for a limited period. Start Saving Now →